| Literature DB >> 34722729 |
Lena Dreikhausen1, Nadine Schulte1, Sebastian Belle1, Philip Weidner1, Johannes Moersdorf2, Christoph Reissfelder3, Matthias P Ebert1, Tianzuo Zhan1.
Abstract
Pancreatic acinar cell carcinoma (ACC) is a rare malignant disease that displays distinct differences to pancreatic ductal adenocarcinoma. Here, we report the case of a patient with ACC and underlying breast cancer susceptibility gene 2 (BRCA2) germline mutation that developed severe pancreatic panniculitis (PP) during the course of the disease. The patient received a multimodal therapy including surgery, systemic chemotherapy, and targeted therapy with the PARP inhibitor olaparib, resulting in an overall survival of 47 months. Findings from this case are compared to the current knowledge on management of ACC and paraneoplastic PP.Entities:
Keywords: Acinar cell carcinoma; BRCA2; FOLFIRINOX; Olaparib; Pancreatic panniculitis
Year: 2021 PMID: 34722729 PMCID: PMC8543339 DOI: 10.1159/000515267
Source DB: PubMed Journal: Visc Med ISSN: 2297-4725